Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study.

Biomedicines · 2020 · PMC7696728 · PMID 33202854

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Finally, sensitivity tests were conducted, which showed a trend of lower NODM incidence in the pitavastatin group than in the atorvastatin or rosuvastatin groups ( Supplementary Figures S1–S4 ). 4.

also in 53,322 other papers

a nonsignificant trendno p-value reported

In conclusion, among patients treated with moderate-intensity statins, a nonsignificant trend of lower risk of NODM was associated with pitavastatin compared with atorvastatin and rosuvastatin based on a real-world clinical database.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.